Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

Full text
Author(s):
Show less -
Shi, Xiaoguang [1] ; Liu, Rengyun [1] ; Basolo, Fulvio [2] ; Giannini, Riccardo [2] ; Shen, Xiaopei [1] ; Teng, Di [1] ; Guan, Haixia [3, 4] ; Shan, Zhongyan [3, 4] ; Teng, Weiping [3, 4] ; Musholt, Thomas J. [5] ; Al-Kuraya, Khawla [6] ; Fugazzola, Laura [7, 8] ; Colombo, Carla [7, 8] ; Kebebew, Electron [9] ; Jarzab, Barbara [10] ; Czarniecka, Agnieszka [10] ; Bendlova, Bela [11] ; Sykorova, Vlasta [11] ; Sobrinho-Simoes, Manuel [12, 13] ; Soares, Paula [12, 13] ; Shong, Young Kee [14] ; Kim, Tae Yong [14] ; Cheng, Sonia [15] ; Asa, Sylvia L. [15] ; Viola, David [16] ; Elisei, Rossella [16] ; Yip, Linwah [17] ; Mian, Caterina [18] ; Vianello, Federica [19] ; Wang, Yangang [20] ; Zhao, Shihua [20] ; Oler, Gisele [21] ; Cerutti, Janete M. [21] ; Puxeddu, Efisio [22] ; Qu, Shen [23] ; Wei, Qing ; Xu, Huixiong [24] ; O'Neill, Christine J. [25] ; Sywak, Mark S. [25] ; Clifton-Bligh, Roderick [25] ; Lam, Alfred K. [26] ; Riesco-Eizaguirre, Garcilaso [27, 28, 29, 30] ; Santisteban, Pilar [29, 30] ; Yu, Hongyu [31] ; Tallini, Giovanni [32] ; Holt, Elizabeth H. [33] ; Vasko, Vasily [34] ; Xing, Mingzhao [1]
Total Authors: 48
Affiliation:
Show less -
[1] Johns Hopkins Univ, Sch Med, Div Endocrinol Diabet & Metab, Lab Cellular & Mol Thyroid Res, Dept Med, Baltimore, MD 21287 - USA
[2] Dept Surg, Div Pathol, I-56126 Pisa - Italy
[3] China Med Univ, Hosp 1, Endocrine Inst, Shenyang 110001, Liaoning - Peoples R China
[4] China Med Univ, Hosp 1, Dept Endocrinol & Metab, Liaoning Prov Key Lab Endocrine Dis, Shenyang 110001, Liaoning - Peoples R China
[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Endocrine Surg, D-55101 Mainz - Germany
[6] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Human Canc Genom Res, Riyadh 12713 - Saudi Arabia
[7] IRCCS Ca Granda Policlin, Fdn Inst Ricovero & Cura Carattere Sci, Milan - Italy
[8] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan - Italy
[9] NCI, Endocrine Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 - USA
[10] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, PL-44101 Gliwice - Poland
[11] Inst Endocrinol, Dept Mol Endocrinol, Prague 11694 - Czech Republic
[12] Univ Porto Ipatimup, Inst Mol Pathol & Immunol, P-4200319 Oporto - Portugal
[13] Univ Porto, Fac Med, P-4200319 Oporto - Portugal
[14] Univ Ulsan, Coll Med, Seoul - South Korea
[15] Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2C4 - Canada
[16] Univ Pisa, WHO, Endocrine Unit, Dept Clin & Expt Med, Collaborating Ctr Study & Treatment Thyroid Dis &, I-56124 Pisa - Italy
[17] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 - USA
[18] Univ Padua, Endocrinol Unit, Dept Med, I-35128 Padua - Italy
[19] IRCCS, Veneto Inst Oncol, I-35128 Padua - Italy
[20] Qingdao Univ, Affiliated Hosp, Dept Endocrinol, Qingdao 266003 - Peoples R China
[21] Univ Fed Sao Paulo, Div Genet, Genet Bases Thyroid Tumor Lab, BR-04039032 Sao Paulo - Brazil
[22] Univ Perugia, Dept Internal Med, I-06100 Perugia - Italy
[23] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Endocrinol, Thyroid Inst, Shanghai 200072 - Peoples R China
[24] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Med Ultrasound, Thyroid Inst, Shanghai 200072 - Peoples R China
[25] Univ Sydney, Endocrine Surg Unit, Sydney, NSW 2052 - Australia
[26] Griffith Univ Gold Coast, Canc Mol Pathol Menzies Hlth Inst Queensland, Southport, Qld 4215 - Australia
[27] Hosp La Paz, Hlth Res Inst, Madrid 28029 - Spain
[28] Hosp Univ Mostoles, Madrid 28029 - Spain
[29] CSIC, Spanish Council Res, Biomed Res Inst, Alberto Sols, Madrid 28029 - Spain
[30] Autonomous Univ Madrid, Madrid 28029 - Spain
[31] Second Mil Med Univ, Changzheng Hosp, Dept Pathol, Shanghai 200003 - Peoples R China
[32] Univ Bologna, Osped Bellaria, Anat Pathol Unit, Dept Med, I-40139 Bologna - Italy
[33] Yale Univ, Sch Med, Dept Internal Med, Endocrine Sect, New Haven, CT 06520 - USA
[34] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 - USA
Total Affiliations: 34
Document type: Journal article
Source: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM; v. 101, n. 1, p. 263-273, JAN 2016.
Web of Science Citations: 74
Abstract

Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support. Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC). Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo). Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC >> FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval {[}CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old. Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC >> FVPTC, providing important clinical implications for specific variant-based management of PTC. (AU)

FAPESP's process: 12/02902-9 - The role of microRNAs in the regulation of C1orf24 expression in thyroid tumors
Grantee:Janete Maria Cerutti
Support Opportunities: Regular Research Grants
FAPESP's process: 13/03867-5 - Analysis of copy number variation (CNV) in pacientes of a family with men 2A and P.G533C mutation in the RET gene: identification of CNV regions associated with genesis and progression of medullary thyroid carcinoma
Grantee:Janete Maria Cerutti
Support Opportunities: Regular Research Grants